When does semaglutide's patent expire?

There isn’t a single expiration date for semaglutide. It’s protected by a family of patents (covering the molecule itself, its salts, formulations, and uses) plus regulatory exclusivities that can extend protection beyond patent expiry. Expiry dates vary by country and by patent family, and they can be affected by term adjustments, lawsuits, and pediatric or data exclusivity.

Rough guidance:
- Primary patent(s) on the semaglutide molecule and key formulations are expected to run into the early-to-mid 2030s in major markets (US, EU), depending on the exact patent family and any term adjustments.
- In the US, new biologics generally receive 12 years of data exclusivity from FDA approval for a new product. This can delay generic/biosimilar competition even after patent expiry, and for semaglutide products (Wegovy, Ozempic) the relevant exclusivity would apply to each product’s own approval date (e.g., Wegovy’s data exclusivity from its approval would extend protection to around a decade after that date, subject to extensions or pediatric addition).
- In the EU, data and marketing exclusivity terms also apply (often combined with supplementary protection certificates), which can push effective protection into the 2030s as well.

If you want a precise date for a specific country or for a specific patent family (e.g., composition-of-matter vs. formulation vs. use patents), tell me the country and which protection you care about, and I can look up or walk you through the exact patent expiry dates.